Metabolic Incorporation of Stable Isotope Labels into Glycans (Application Note 23)
- Metabolic Incorporation of Stable Isotope Labels into Glycans (Application Note 23)
The glycan standards available are in their 13C6-labeled and unlabeled form. These encompass a broad range of categories (e.g., N-linked, O-linked, and fucosylated) and have been highly characterized using a number of analytical techniques (e.g., 1H NMR and ESI-MS). The standards are supplied as purified powders in 500 pmol quantities (alternate quantities available upon request) and can be used for a variety of applications (e.g., health and disease assessment).
Common Symbol Nomenclature for Unlabeled Monosaccharides:
Note: Labeled monosaccharide symbols (e.g.,13C6 galactose) contain a black asterisk.
Frequently Asked Questions
What is the symbol nomenclature for denoting glycans in chemical structures?
The symbols adhere to the modified IUPAC nomenclature, as recommended by the glycomics consortium network. This defines the sugar type and its isomers. The representations of common monosaccharides and linkages are shown above (as illustrated in the "Essentials of Glycobiology" reference below).
How many labeled/unlabeled glycan pairs do you offer?
Our current inventory is 11 pairs, but please inquire if a corresponding analogue of an existing standard is required or a certain new pair is of interest.
How many N-glycan standards do you offer?
We currently offer 32 N-linked glycans. Please inquire for the availability of other N-glycans.
Can alternate glycans be made available upon request?
Yes, provided they can be synthesized through enzymatic and/or chemical means. Please submit your request to your local sales representative/distributor or complete the on-line custom synthesis form. Required is the structure(s), desired quantities, and labeling pattern(s) (if applicable). We will contact you shortly thereafter regarding its feasibility.
Taniguchi, N.; Kizuka, Y. 2015. Glycans and cancer: role of N-glycans in cancer biomarker, progression and metastasis, and therapeutics. Adv Cancer Res, 126, 11-51.
Schedin-Weiss, S.; Winblad, B.; Tjernberg, L.O. 2014. The role of protein glycosylation in Alzheimer disease. FEBS J, 281(10), 46-62.
Varki, A; Cummings, R.D. et al. 2009. Essentials of Glycobiology, 2nd edition. ISBN-13:9780879697709
Kevin Millis, PhD
Senior Scientist, Application Development Manager
Kevin Millis, PhD, is the Senior Scientist and Market Development Manager for all NMR and Mass Spectrometry product lines. Kevin is responsible for Technical Services both internally and externally for all CIL customers as well as being responsible for the application and market development for the CIL products.
Andrew Percy, PhD
Senior Applications Chemist - Mass Spectrometry
Dr. Andrew Percy is the Senior Applications Chemist for Mass Spectrometry. His responsibilities minimally involve overseeing product development, identifying new product market opportunities, assisting in the analysis of products for MS ‘omics applications, and providing technical support to customers.